Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Cancer Chemother Pharmacol · 2017 · PMC5686255 · PMID 29051995

Europe PMC DOI

hedged sentence

0.1420

closest p · 2.8× alpha

0.1420

boldest claim

The sentences

did not reach statistical significancep = 0.142not close (p > 0.1)

However, possibly due to the limited size of the sarcoma subgroup in our cohort and the relatively lower effect size of pazopanib in sarcoma, our result did not reach statistical significance in univariate analysis (progression free survival of 18.7 vs. 8.8 weeks, p = 0.142, Fig. 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.